CORRECTION



## Correction: Quality Tolerance Limits' Place in the Quality Management System and Link to the Statistical Trial Design: Case Studies and Recommendations from Early Adopters

Marion Wolfs<sup>1</sup> · Łukasz Bojarski<sup>2</sup> · Steve Young<sup>3</sup> · Lynne Cesario<sup>4</sup> · Marcin Makowski<sup>5</sup> · Linda B. Sullivan<sup>6</sup>

Published online: 10 June 2023 © The Author(s) 2023

## Correction: Therapeutic Innovation & Regulatory Science https://doi.org/10.1007/s43441-023-00504-6

The article Quality Tolerance Limits' Place in the Quality Management System and Link to the Statistical Trial Design: Case Studies and Recommendations from Early Adopters, written by Marion Wolfs, Łukasz Bojarski, Steve Young, Lynne Cesario, Marcin Makowski, and Linda B. Sullivan was originally published electronically on the publisher's internet portal on 27 March 2023 without open access. With the author(s)' decision to opt for Open Choice, the copyright of the article changed on 24 May 2023 to ©The Author(s) 2023, and the article is forthwith distributed under a Creative Commons Attribution CC BY 4.0.

## **Open Access**

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at https://doi.org/10.1007/ s43441-023-00504-6.

Marion Wolfs Mwolfs1@its.jnj.com

- <sup>1</sup> Integrated Data Analytics and Reporting, Janssen Research and Development, Graaf Engelbertlaan 75, 4837DS Breda, Netherlands
- <sup>2</sup> Development Operations, AstraZeneca R&D BioPharmaceuticals, ul. Postepu 14, 02-675 Warsaw, Poland
- <sup>3</sup> CluePoints Inc, King of Prussia, PA, USA
- <sup>4</sup> Pfizer R&D, New York, NY, USA
- <sup>5</sup> Data Strategy and Management, GlaxoSmithKline GmbH & Co. KG, Prinzregentenpl. 9, 81675 Munich, Germany
- <sup>6</sup> Metrics & Performance Management, WCG, Indianapolis, IN, USA